Bridges Investment Counsel Decreased Its Johnson & Johnson Com (JNJ) Holding; LA Jolla Pharmaceutical Company (LJPC) SI Increased By 3.17%

Bridges Investment Counsel Inc decreased Johnson & Johnson Com (JNJ) stake by 58.61% reported in 2017Q3 SEC filing. Bridges Investment Counsel Inc sold 41,987 shares as Johnson & Johnson Com (JNJ)’s stock rose 6.85%. The Bridges Investment Counsel Inc holds 29,657 shares with $3.86 million value, down from 71,644 last quarter. Johnson & Johnson Com now has $381.19 billion valuation. The stock increased 0.13% or $0.18 during the last trading session, reaching $141.89. About 5.13M shares traded. Johnson & Johnson (NYSE:JNJ) has risen 12.54% since January 9, 2017 and is uptrending. It has underperformed by 4.16% the S&P500.

LA Jolla Pharmaceutical Company (NASDAQ:LJPC) had an increase of 3.17% in short interest. LJPC’s SI was 3.56 million shares in January as released by FINRA. Its up 3.17% from 3.45 million shares previously. With 153,300 avg volume, 23 days are for LA Jolla Pharmaceutical Company (NASDAQ:LJPC)’s short sellers to cover LJPC’s short positions. The SI to LA Jolla Pharmaceutical Company’s float is 33.17%. The stock decreased 6.19% or $1.86 during the last trading session, reaching $28.17. About 383,391 shares traded. La Jolla Pharmaceutical Company (NASDAQ:LJPC) has risen 128.65% since January 9, 2017 and is uptrending. It has outperformed by 111.95% the S&P500.

Among 8 analysts covering La Jolla Pharmaceutical Company (NASDAQ:LJPC), 6 have Buy rating, 2 Sell and 0 Hold. Therefore 75% are positive. La Jolla Pharmaceutical Company has $90.0 highest and $20.0 lowest target. $46.86’s average target is 66.35% above currents $28.17 stock price. La Jolla Pharmaceutical Company had 16 analyst reports since August 11, 2015 according to SRatingsIntel. On Monday, June 12 the stock rating was maintained by Jefferies with “Buy”. The stock has “Buy” rating by J.P. Morgan on Wednesday, August 30. The company was maintained on Tuesday, September 8 by Chardan Capital Markets. On Tuesday, February 9 the stock rating was initiated by Cowen & Co with “Outperform”. J.P. Morgan downgraded La Jolla Pharmaceutical Company (NASDAQ:LJPC) rating on Friday, December 8. J.P. Morgan has “Sell” rating and $20.0 target. The stock of La Jolla Pharmaceutical Company (NASDAQ:LJPC) has “Buy” rating given on Thursday, August 31 by Jefferies. The firm has “Underweight” rating given on Friday, December 8 by JP Morgan. The firm has “Buy” rating given on Monday, July 24 by Jefferies. The company was initiated on Tuesday, May 24 by Lake Street. The stock of La Jolla Pharmaceutical Company (NASDAQ:LJPC) earned “Hold” rating by Zacks on Tuesday, August 11.

La Jolla Pharmaceutical Company, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for life-threatening diseases. The company has market cap of $623.83 million. It engages in developing LJPC-501, a formulation of angiotensin II for the potential treatment of catecholamine-resistant hypotension; and LJPC-401, a formulation of synthetic human hepcidin for the treatment of conditions characterized by iron overload, such as hereditary hemochromatosis, beta thalassemia, sickle cell disease, and myelodysplastic syndrome. It currently has negative earnings. The firm is also developing LJPC-30S, which is the gentamicin derivative program for the potential treatment of serious bacterial infections and rare genetic disorders, such as cystic fibrosis and Duchenne muscular dystrophy.

Since December 29, 2017, it had 0 insider buys, and 1 sale for $323,208 activity. 10,000 La Jolla Pharmaceutical Company (NASDAQ:LJPC) shares with value of $323,208 were sold by Douglass Laura L..

Investors sentiment decreased to 1.61 in Q3 2017. Its down 0.20, from 1.81 in 2017Q2. It is negative, as 10 investors sold La Jolla Pharmaceutical Company shares while 21 reduced holdings. 25 funds opened positions while 25 raised stakes. 23.31 million shares or 1.99% less from 23.78 million shares in 2017Q2 were reported. Moreover, Raymond James Assoc has 0% invested in La Jolla Pharmaceutical Company (NASDAQ:LJPC). Peak6 Limited Partnership holds 0% of its portfolio in La Jolla Pharmaceutical Company (NASDAQ:LJPC) for 3,267 shares. Swiss Commercial Bank stated it has 29,400 shares or 0% of all its holdings. Wells Fargo And Mn reported 17,056 shares or 0% of all its holdings. Moreover, Millennium Mngmt Ltd Liability Co has 0% invested in La Jolla Pharmaceutical Company (NASDAQ:LJPC). Bnp Paribas Arbitrage Sa accumulated 1,736 shares. Credit Suisse Ag stated it has 27,425 shares or 0% of all its holdings. Emory University has invested 1.45% of its portfolio in La Jolla Pharmaceutical Company (NASDAQ:LJPC). Oak Ridge Invs Limited Liability Corporation invested 0.59% of its portfolio in La Jolla Pharmaceutical Company (NASDAQ:LJPC). Tiaa Cref Lc, a New York-based fund reported 46,063 shares. Baker Bros Advsrs L P holds 154,675 shares or 0.04% of its portfolio. Great West Life Assurance Can owns 2,654 shares. Axiom Lc De holds 0.04% of its portfolio in La Jolla Pharmaceutical Company (NASDAQ:LJPC) for 56,371 shares. Sei reported 1,006 shares. Ny State Common Retirement Fund invested in 0% or 18,300 shares.

Investors sentiment is 0.83 in 2017 Q3. Its the same as in 2017Q2. It is the same, as 45 investors sold JNJ shares while 871 reduced holdings. only 111 funds opened positions while 645 raised stakes. 1.71 billion shares or 0.90% less from 1.73 billion shares in 2017Q2 were reported. Sectoral Asset Mngmt holds 3.94% or 235,349 shares. Country Club Tru Company Na stated it has 2.33% in Johnson & Johnson (NYSE:JNJ). Heritage Invsts Mngmt has 168,286 shares. Jackson Wealth Mgmt Lc holds 1.34% or 37,063 shares. Brave Asset Inc reported 16,643 shares. Legg Mason Asset (Japan) Ltd reported 2.2% stake. San Francisco Sentry Inv (Ca) holds 1.5% in Johnson & Johnson (NYSE:JNJ) or 34,304 shares. Raab & Moskowitz Asset Mgmt Ltd Liability Corporation stated it has 2.9% in Johnson & Johnson (NYSE:JNJ). 96,960 were accumulated by Woodstock. New England And Mngmt has 3.1% invested in Johnson & Johnson (NYSE:JNJ) for 32,592 shares. Cincinnati Indemnity reported 25,000 shares. Dana Invest Advisors Inc accumulated 265,269 shares. Commercial Bank Of Stockton has 0.66% invested in Johnson & Johnson (NYSE:JNJ) for 11,194 shares. 17,145 were accumulated by Roof Eidam And Maycock Adv. Monroe Bank & Tru Mi invested in 0.45% or 11,336 shares.

Among 23 analysts covering Johnson & Johnson (NYSE:JNJ), 12 have Buy rating, 5 Sell and 6 Hold. Therefore 52% are positive. Johnson & Johnson has $165 highest and $90 lowest target. $136.94’s average target is -3.49% below currents $141.89 stock price. Johnson & Johnson had 84 analyst reports since August 7, 2015 according to SRatingsIntel. The stock has “Hold” rating by Stifel Nicolaus on Tuesday, July 18. The company was maintained on Wednesday, October 18 by Jefferies. Standpoint Research initiated the stock with “Sell” rating in Friday, May 20 report. Piper Jaffray maintained the shares of JNJ in report on Tuesday, July 18 with “Hold” rating. The stock of Johnson & Johnson (NYSE:JNJ) earned “Buy” rating by RBC Capital Markets on Friday, September 22. The stock has “Buy” rating by RBC Capital Markets on Sunday, August 27. The company was maintained on Thursday, October 19 by Credit Suisse. The stock has “Outperform” rating by RBC Capital Markets on Wednesday, July 20. As per Wednesday, October 11, the company rating was upgraded by Jefferies. The company was downgraded on Friday, July 21 by Alembic.

Analysts await Johnson & Johnson (NYSE:JNJ) to report earnings on January, 23. They expect $1.72 EPS, up 8.86% or $0.14 from last year’s $1.58 per share. JNJ’s profit will be $4.62B for 20.62 P/E if the $1.72 EPS becomes a reality. After $1.90 actual EPS reported by Johnson & Johnson for the previous quarter, Wall Street now forecasts -9.47% negative EPS growth.